Tekla Life Sciences Investors (HQL) AI Stock Analysis

Established in 1992, Tekla Life Sciences Investors operates as a closed-ended equity mutual fund managed by Tekla Capital Management LLC. The fund specializes in investments within the global life sciences industry, focusing on growth stocks of small-cap companies. Its target areas include biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies, agriculture, and environmental management. Investment decisions rely on fundamental analysis, evaluating management expertise, market position, technological advancements, and capital access. The fund benchmarks its investment performance against the NASDAQ Biotech Index and the S&P 500 Index.

Top-line results reflect investment performance fluctuations typical of an equity fund. Revenue rose to $86.7M in FY2024 before easing 0.3% to $86.4M in FY2025, where net income reached $85.6M with a net margin of 99.1% and diluted EPS of $2.74. This followed volatile prior periods, including revenue of -$103.3M in FY2022 and $23.5M in FY2023. Over the five years from FY2020 to FY2025, revenue compound annual growth was -7.0%. For the trailing twelve months ended March 31, 2026, revenue totaled $1.1M with diluted EPS of $6.64. In the latest quarter ended March 31, 2026, quarterly revenue fell 60.8% year-over-year, while quarterly earnings grew 259.4%.

As of March 31, 2026, Tekla Life Sciences Investors held $851,602 in cash and short-term investments against total assets of $563.2M and shareholders' equity of $560.8M. The fund reported a current ratio of 2.58. In FY2025, operating cash flow stood at -$2.3M and free cash flow was -$2.3M, with capital expenditures of $5. Cash outlays included $31.6M paid in dividends during FY2025, while the fund's share count expanded by 23.3% over five years.

At its last close of $16.78 on October 16, 2026, the fund traded at an enterprise value of $509.4M and a trailing price-to-earnings ratio of 2.5x, well below the 12.1x median of its US-listed Financial Services peers. Its price-to-sales ratio was 3.1x versus the peer median of 3.2x, while price-to-book was 1.1x. Over the past year, the stock generated a 14.5% return, trailing the 16.8% return of the S&P 500 (SPY). Over five years, its 41.9% return lagged the S&P 500 return of 83.0%.

Tekla Life Sciences Investors pays a quarterly dividend with an annual forward payout of $2.24 per share, translating to a dividend yield of 13.35%. The payout ratio is 51.1%. The fund has paid dividends for 31 consecutive years, delivering a 5-year annualized dividend growth rate of 3.1%. Its last ex-dividend date was August 24, 2026.

The fund has recorded 2 EPS beats out of its last 4 reported quarters. No consensus price targets, earnings projections, or analyst recommendations are currently published for the shares. With an institutional ownership stake of 38.3% and insider ownership at 0.0%, the fund trades with a beta of 0.73, indicating lower price volatility relative to the broader market.

This page is an AI-written research summary of Tekla Life Sciences Investors (HQL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: HQL income statement, HQL balance sheet, HQL key metrics, HQL chart. See the HQL stock overview for the latest quote and news.